MaxCyte's total revenue for Q2 2025 decreased by 18% year-over-year to $8.5 million, primarily due to a significant drop in SPL Program-related revenue. However, core business revenue saw an 8% increase to $8.2 million. The company reported a net loss of $12.4 million and updated its full-year 2025 guidance, lowering revenue expectations due to evolving operating environments.

MaxCyte reported a total revenue of $10.4 million for the first quarter of 2025, an 8% decrease compared to the same period in 2024. However, core business revenue increased by 1% to $8.2 million. The company added one new SPL client, TG Therapeutics, bringing the total number of active SPLs to 29. Net loss for the quarter was $10.3 million.

MaxCyte's total revenue for Q4 2024 decreased by 45% to $8.7 million compared to Q4 2023, primarily due to one-time approval milestones in the prior year. However, core business revenue increased by 20% to $8.6 million. The company ended the year with $190.3 million in cash, cash equivalents, and investments.

MaxCyte reported a 2% increase in total revenue, reaching $8.2 million in Q3 2024. Core business revenue grew by 23% to $8.1 million, driven by a 39% increase in cell therapy revenue. The company signed six new SPL clients year-to-date, bringing the total to 29. MaxCyte is also evaluating cost reduction opportunities, including a potential cancellation of its AIM listing.

MaxCyte reported a 15% increase in total revenue for Q2 2024, reaching $10.4 million, driven by a significant 279% increase in Strategic Platform License (SPL) Program-related revenue. However, core business revenue declined by 9%. The company signed five new SPL clients year-to-date and affirmed its full-year 2024 core business revenue guidance while increasing SPL Program-related revenue guidance.

MaxCyte reported a 32% increase in total revenue, reaching $11.3 million, driven by a 5% increase in core business revenue and a 292% increase in Strategic Platform License (SPL) Program-related revenue. The company signed four new SPL clients year-to-date, bringing the total to 27 SPL partners.

MaxCyte reported a mixed performance for Q4 2023. Total revenue increased by 26% year-over-year, driven by a significant increase in Strategic Platform License (SPL) Program-related revenue. However, core business revenue declined by 32% compared to the same period in the previous year. The company's net loss was $5.3 million, slightly higher than the net loss of $4.8 million in Q4 2022.

MaxCyte reported a decrease in total revenue for Q3 2023, primarily due to a decline in core business revenue, although SPL Program-related revenue increased. The company is addressing industry challenges and focusing on targeted investments to support the cell and gene therapy market.

Maxcyte reported a 6% decrease in total revenue for Q2 2023, amounting to $9.0 million compared to $9.6 million in Q2 2022. Core business revenue also declined by 14% to $8.3 million. The company signed five SPL partnerships year-to-date, bringing the total to 23. MaxCyte now expects core revenue for 2023 to be comparable to 2022 and SPL program-related revenue expectations remain unchanged at approximately $6 million for the year.

MaxCyte reported a 26% decrease in total revenue for Q1 2023, amounting to $8.6 million, compared to $11.6 million in Q1 2022. Despite the revenue decline, the company highlighted the addition of two new SPL partnerships and progress towards potential commercial approval of a product enabled by their platform.

MaxCyte reported a 22% increase in total revenue for the fourth quarter of 2022, reaching $12.4 million. Core business revenues grew by 4%, driven by cell therapy and drug discovery customer growth. The company's SPL program-related revenue was $1.9 million. MaxCyte provided initial 2023 revenue guidance, expecting total revenue growth of 21% to 26% over 2022.

MaxCyte, Inc. announced financial results for the third quarter ended September 30, 2022. Total revenue increased by 5% compared to the third quarter of 2021, with core business revenues growing by 22%. The company is reiterating its 2022 guidance for core business revenue growth to be approximately 30%.

MaxCyte reported a 35% increase in total revenue for Q2 2022, driven by a 45% growth in core business revenues and a 61% increase in revenue from cell therapy customers. The company is raising its 2022 core revenue growth guidance to approximately 30% and expects SPL Program-related revenue to be approximately $4 million for the full year.